Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 5,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: In Utero SARS-CoV-2 Exposure
Interventions: In Utero Exposure to SARS-CoV-2; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 9 Months and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Hemophilia A
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Conditions: Covid19
Interventions: Covid-19+ observational; Other
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Peripheral Intravenous Vein Catheter Phlebitis, Intravenous Infection
Interventions: B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter, B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Osteomyelitis
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Bacterial Infections, Infection
Interventions: BC-3781, Vancomycin; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 6 more

Conditions: Surgical Wound Infection
Interventions: Warming of surgical incision, Warming dressing without actual warming; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Urinary Tract Infection
Interventions: Lactin-V, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Quinolone Resistance, ESBL, Klebsiella Species, Infection
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Covid19, Pneumonia, Viral
Interventions: alpha1-proteinase inhibitor, Antiviral Agents; Drug
Lead sponsor: Blessing Corporate Services, Inc; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Hannibal, Missouri

Conditions: Premature Infant, Chronic Respiratory Disease, Neuromuscular Diseases, Healthy, Bronchopulmonary Dysplasia, Pulmonary Vein Stenoses
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Days to 40 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions: RBX2660; Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 46
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more

Conditions: Adenovirus Infection
Interventions: Viralym-A; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Clotrimazole, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Los Angeles, California • Oakland, California • San Francisco, California + 12 more

Conditions: Influenza
Interventions: 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo; Drug
Lead sponsor: Biota Scientific Management Pty Ltd; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 70
States / cities: Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: 15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 3
States / cities: Hollywood, Florida • South Miami, Florida • Endwell, New York

Conditions: Amebiasis, Cryptosporidiosis, Giardiasis, Parasitic Disease, Parasitic Intestinal Disease, Gastrointestinal Helminth Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1977 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Oral Herpes Simplex
Interventions: BTL TML HSV, Matching placebo; Drug
Lead sponsor: Beech Tree Labs, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Lexington, Kentucky • Buffalo, New York • Norwich, New York + 1 more

Conditions: COVID-19
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Antibiotics, Upper Respiratory Infections, Safety-Net Hospitals, Behavioral Economics, Choosing Wisely
Interventions: Nudge using Behavioral Economic Interventions, Standard Practices to Reduce Health System Antibiotic Prescription; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Preterm Birth
Interventions: Targeted Nurse Home Visits, Conventional prenatal/postpartum care; Behavioral · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Spiramycin; Drug
Lead sponsor: Rhone-Poulenc Rorer; Industry
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Diego, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more

Conditions: Acute Respiratory Infections (ARIs)
Interventions: Rapid point of care test to detect host immune response in ARI; Diagnostic Test
Lead sponsor: Lumos Diagnostics; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Fullerton, California • Pasadena, California • Miami, Florida + 5 more

Search by objective public record fields.

In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life

Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia

Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients

Evaluating the Role of the Guidewire in Peripheral Intravenous Access

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis (PCT)

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Local Warming of Surgical Incisions

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

Genesis Electrical Impedance Tomography (EIT): A Preliminary Study

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)

A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

Parasitic Infections of the Gastrointestinal Tract

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections

Tennessee Connections for Better Birth Outcomes

A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

FebriDx® Method Comparison Study Protocol